Advertisement

Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 600x80px
Document › Details

Bloomberg News [Mulier, Thomas / Kresge, Naomi]. (12/22/17). "Press Release: Roche to Buy U.S. Cancer-Drug Maker Ignyta for $1.7 Billion. Deal Comes Five Weeks after Bayer Licenses Similar Drug".

Organisations Organisation Roche (Group)
  Organisation 2 Ignyta Inc. (Nasdaq: RXDX)
  Group Roche (Group)
Products Product entrectinib
  Product 2 larotrectinib (LOXO-101)
Index terms Index term Ignyta–Roche: investment, 201712– cash tender offer $1.7b for all outstanding shares at $27/share
  Index term 2 Bayer–Loxo Oncology: TRK inhibitors, 201711– ww collab $400m upfront + $650m milestones developm of larotectinib + LOXO-195
     


   
Record changed: 2017-12-28

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for Roche (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 600x80px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 120x180px